UNITED STATES SECURITIES AND EXCHANGE COMMISSION March 19, 2018

ORDER GRANTING CONFIDENTIAL TREATMENT UNDER THE SECURITIES EXCHANGE ACT OF 1934

Fate Therapeutics, Inc.

File No. 1-36076 - CF#35925

Fate Therapeutics, Inc. submitted an application under Rule 24b-2 requesting an extension of a previous grant of confidential treatment for information it excluded from the Exhibits to a Form 10-K filed on March 12, 2015.

Based on representations by Fate Therapeutics, Inc. that this information qualifies as confidential commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded information from the following exhibit(s) will not be released to the public for the time period(s) specified:

Exhibit 10.23	through March 12, 2021
Exhibit 10.24	through March 12, 2021
Exhibit 10.25	through March 12, 2021
Exhibit 10.26	through March 12, 2021

For the Commission, by the Division of Corporation Finance, pursuant to delegated authority:

Brent J. Fields Secretary